New immune therapy trial offers hope for rare thymus cancers

This study is testing whether the immunotherapy drug avelumab is safe and can help control thymoma or thymic carcinoma that has grown or returned after standard platinum-based chemotherapy. It involves 56 adults who will receive avelumab by IV infusion every two weeks until side effects become intolerable or their cancer worsens. The goal is to see if this drug, which helps the immune system fight cancer, can shrink tumors or stop their growth in these rare cancers.